Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 856 | 133 | 717 |
| Samples | 427 | 80 | 344 |
| Peptides | 315 | 60 | 271 |
Function
UGT2A2 · UDP glucuronosyltransferase family 2 member A2
The protein encoded by this gene belongs to the UDP-glycosyltransferase family. Members of this protein family play a role in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. The encoded enzyme is expressed in the olfactory neuroepithelium, which lines the posterior nasal cavity and is exposed to a wide range of odorants and airborne toxic compounds. Hence, this protein has been suggested to be involved in clearing lipophilic odorant molecules from the sensory epithelium. This gene shares exon structure with the UDP glucuronosyltransferase 2A1 family member, which encodes N-terminally distinct isoforms. Polymorphisms in this gene may be associated with the loss of taste and smell that is reported by some individuals during SARS-CoV-2 infection. [provided by RefSeq, Jan 2022].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 298 amino-acid changes on canonical ENST00000604629 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in UGT2A2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in UGT2A2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 10/210 5% | 99/1899 5% |
| Endometrial Carcinoma | 3/42 7% | 22/612 4% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Non-Small Cell Lung Carcinoma | 16/304 5% | 26/1390 2% |
| Chondrosarcoma | 2/14 14% | 0/75 0% |
| Hodgkins Lymphoma | 3/16 19% | 0/122 0% |
| Rhabdomyosarcoma | 1/33 3% | 3/171 2% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Bladder Carcinoma | 2/58 3% | 12/956 1% |
| Mesothelioma | 2/62 3% | 1/165 1% |
| Plasma Cell Myeloma | 4/44 9% | 0/305 0% |
| Colorectal Carcinoma | 8/143 6% | 29/3239 1% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 4/810 0% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Other Solid Cancers | 3/94 3% | 12/1515 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Glioma | 1/52 2% | 16/2127 1% |
| Ovarian Carcinoma | 4/109 4% | 4/998 0% |
| Neuroendocrine Tumour | 3/154 2% | 2/577 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 11/1592 1% |
| Kidney Carcinoma | 0/85 0% | 13/1862 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Gastric Carcinoma | 0/74 0% | 11/1809 1% |
| Hepatocellular Carcinoma | 0/46 0% | 11/2210 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Breast Carcinoma | 4/144 3% | 11/3264 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Head and Neck Carcinoma | 2/85 2% | 4/1574 0% |
Mutation Distribution
Where UGT2A2 is mutated · all tissues, split by cell line vs tissue
How many mutations in UGT2A2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
Mutations
All 856 mutations in UGT2A2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|